SightfileU.S. market data from official filings

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Name: TAKEDA PHARMACEUTICAL CO LTD (TAK) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001395064 · EDGAR filings · Updated 2026-07-13

TAKEDA PHARMACEUTICAL CO LTD (TAK) has 357 institutional managers reporting positions valued at $1.82B per the latest 13F reporting period.

Institutional managers

357

Reported 13F value

$1.82B

Latest updates

2026-07-13 — Notice of proposed sale filed (Form 144)
2026-07-13 — Notice of proposed sale filed (Form 144)
2026-07-13 — Notice of proposed sale filed (Form 144)
2026-07-13 — Notice of proposed sale filed (Form 144)
2026-07-13 — Notice of proposed sale filed (Form 144)
2026-07-13 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, TAKEDA PHARMACEUTICAL CO LTD has 357 institutional holders.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 24 reporting insiders, with a net reported value of $0.

Related companies

ADMA BIOLOGICS (ADMA) · SURGERY PARTNERS INC (SGRY) · RELAY THERAPEUTICS INC (RLAY) · GRAIL INC (GRAL) · SIONNA THERAPEUTICS INC (SION) · NURIX THERAPEUTICS INC (NRIX)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.